Therapeutic Antibodies – Multimedia

The development of antibodies for diagnostics or therapeutics requires comprehensive characterization of affinity, specificity and mechanism of action. In particular, antibody-drug conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Monoclonal antibody (mAb)–based therapeutics have been very successful in treating various diseases, including cancer. The manufacturing of these therapeutic antibodies is a complex operation with low levels of aggregates being a critical quality attribute of the final product, as this will impact the biological activity.

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.

According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. Furthermore, recent estimates predict that as many as one in two people could develop a form of cancer in their lifetime.

In recent years, different therapeutic antibody modalities have been developed to address different therapeutic needs.

In this episode of Opinionated Science we dive into the world of therapeutic antibodies with Bio-Rad.

Antibody drug conjugates (ADCs) are biotherapeutics, composed of small molecule drugs conjugated to an antibody scaffold, that have very complex molecular structures.

This is especially critical for bispecific antibodies, which are regarded as the second generation of antibody cancer therapies.

In this episode, we speak with Andris Abramenkovs, product manager of CellCelector technology at Sartorius.